Recruiting

Testing a new immune-boosting cancer treatment in early trials

Plain-English translation of NCT05341557 on ClinicalTrials.gov ↗ · Source last updated January 2025 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is an early-stage trial testing a new medication called that helps your immune system fight cancer. The study will enroll about 110 patients with advanced solid tumors or lymphoma that has come back or stopped responding to standard treatment. Researchers want to find the safest and most effective dose of this medication and understand how it works in your body.

Current cancer treatments don't work for everyone, and some patients develop resistance over time. This medication works by removing a 'brake' that cancer cells use to hide from the immune system, potentially allowing your body to fight cancer more effectively.

Do you qualify?

You likely qualify if…

you are at least 18 years old (and under 65 for the first phase of the study)
you have been diagnosed with advanced cancer or lymphoma that has progressed despite standard treatment, or standard treatment didn't work for you
you are in good enough health to handle treatment (your doctor will assess this using a standard performance scale)
you have measurable cancer that can be seen on scans or imaging tests
you have not previously received similar immune-based cancer treatments within the past 28 days

You likely don't qualify if…

you have previously received other immune checkpoint inhibitor treatments within the last 28 days
you experienced a severe allergic or immune reaction to previous cancer immunotherapy drugs
you are taking high-dose steroid medications (equivalent to 10 mg or more of prednisone daily)
you have had major surgery within the past 4 weeks or have an active infection
you are pregnant, breastfeeding, or have an autoimmune disease or other serious health conditions that your doctor thinks make this trial unsafe for you

What participation looks like

You will take a daily oral capsule of the medication. The trial has two phases: in the first phase, the dose gradually increases across groups of patients to find the safest amount; in the second phase, patients receive the recommended dose. Each treatment cycle lasts 21 days, and you will likely have regular clinic visits for blood tests, scans, and checkups to monitor how the medication is working and any side effects you may experience.

AI-generated summary from trial data · Jun 24, 2026 · Not medical advice

Trial locations(4 sites)

China

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Chaoyang, Beijing Municipality

Cangzhou Central Hospital, Cangzhou, Hebei

Tianjin Cancer Hospital, Tianjin, Tianjin Municipality

Tianjin Medical University General Hospital, Tianjin, Tianjin Municipality